COMMUNIQUÉS West-GlobeNewswire

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
02/02/2024
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024
DALLAS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of [...]
GRI Bio Announces Pricing of $5.5 Million Public Offering
02/02/2024
LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc . (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the [...]
SAB Biotherapeutics Announces Executive Leadership Change
02/02/2024
SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired [...]
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
02/02/2024
Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- [...]
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
02/02/2024
PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of [...]
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
02/02/2024
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host [...]
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
02/02/2024
- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality was reported over the [...]
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
02/02/2024
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* -- -- Current Nitisinone market is estimated to exceed $50 million annually -- -- Product is now available exclusively [...]
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
02/02/2024
Media Release COPENHAGEN, Denmark; February 2, 2024 Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (Nasdaq: GMAB ) and Pfizer, Inc. (NYSE PFE) today a nnounced that the European Medicines [...]
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
02/02/2024
Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding Ronapreve TM (a)(b) , revenues increased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022 [...]
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
02/02/2024
TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application [...]
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
02/02/2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals (“Inmagene”) [...]
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed
02/02/2024
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024 Company announcement No. 07 On January 29, 2024, following the satisfaction of all conditions precedent, the [...]
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
02/02/2024
SHANGHAI, China, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units
02/02/2024
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 01, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX [...]
Fractyl Health Announces Pricing of Initial Public Offering
02/02/2024
LEXINGTON, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today [...]

Pages